Preclinical
February 14, 2024
Molecular Cancer Therapeutics
Design and evaluation of ZD06519, a novel camptothecin payload for antibody drug conjugates
Petersen et al.
Preclinical
January 17, 2024
PepTalk
Engineering a Pure and Stable Heterodimeric IgA for the Development of Multispecific Therapeutics
Meghan Verstraete
Preclinical
November 4, 2023
SITC
TriTCE Co-Stim: A novel trispecific T cell engager platform, with integrated CD28 costimulation, engineered to widen the therapeutic window for treatment of poorly infiltrated tumors
Newhook et al.
Preclinical
November 4, 2023
SITC
TriTCE CPI: a novel trispecific T cell engager platform with integrated PD-1/PD-L1 checkpoint inhibition engineered for the treatment of immunosuppressed tumors
Verstraete et al.
Zanidatamab
October 23, 2023
ESMO
Zanidatamab (ZW25), a HER2-Targeted Bispecific Antibody, in Combination With Chemotherapy and Tislelizumab in Patients With Advanced HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma: Updated Results From a Phase 1b/2 Study
Keun-Wook Lee, et al.
Preclinical
October 18, 2023
World ADC San Diego
ZW220 – A Potential First-in-Class TOPO1i ADC for the Treatment of NaPi2b-Expressing Solid Tumors
Andrea Hernández Rojas
Preclinical
October 16, 2023
World ADC San Diego
ZW251 – A novel glypican-3 targeting ADC bearing a topoisomerase I inhibitor payload
Laurence Madera
Zanidatamab Zovodotin
October 13, 2023
AACR-EORTC-NCI
Phase 1 Study of Zanidatamab Zovodotin (ZW49): Safety Profile and Recommended Dose (RD) in Patients with Human Epidermal Growth Factor 2 (HER2)-positive Solid Cancers
Oh et al.
Preclinical
October 12, 2023
AACR-EORTC-NCI
Refining our understanding of ADCs: Drug development insights from 40 years of data
Raffaele Colombo
Preclinical
October 10, 2023
Festival of Biologics
TOPO1i ADC Platform From Concept to Pipeline Application
Mark Petersen
Preclinical
October 2, 2023
World Bispecific Summit
Engineering Trispecific T-cell Engagers to Address Biological Challenges in the Treatment of Solid Tumors
Nina Weisser
Preclinical
June 12, 2023
Journal of Medicinal Chemistry
Structure–Activity Relationships of Bis-Intercalating Peptides and Their Application as Antibody–Drug Conjugate Payloads
Petersen et al.
